Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $153.00. The ...

Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic ...

Pharmacovigilance is extremely important for every pharmaceutical company. This month is our safety and pharmacovigilance focus, so pharmaphorum's Hannah Blake interviewed Amgen's Vice President ...

A U.S. appeals court temporarily blocked a generic version of Novartis' Entresto, and new price limits challenge pharma as ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

The looming threat of a TikTok ban is set to become reality, though some pharma marketers view the situation as an opportunity.